Can serum C-Reactive Protein and Procalcitonin levels associate with carpal tunnel syndrome?

Abstract

Objective: The purpose of this study was to examine whether an increase occurs in serum C-reactive protein (CRP) and procalcitonin (PCT) levels in patients with carpal tunnel syndrome (CTS). Material and Methods: Thirty-six patients who have CTS due to electrophysiological tests and 40 healthy individuals were included the study. Boston Questionnaire (BQ) was used to assess the functional and clinical status of the patients. Also, CRP and PCT levels were investigated. Correlations between such parameters (electrophysiological findings, BQ results, and clinical findings) were evaluated. Results: CTS and control subjects had similar CRP levels, whereas there was significant elevation in PCT among CTS patients. Serum PCT activity did not correlate with subunits of BQ (p> 0.05). Conclusion: The results of this small study showed significant PCT increases in patients with CTS. Further studies in this regard may help to clarify the diagnostic and or follow-up value of PCT in patients with CTS.

Keywords

• Carpal tunnel syndrome,Procalcitonin

Kaynakça

1. 1. Michelsen H, Posner MA. Medical history of carpal tunnel syndrome. Hand Clin. 2002; 18: 257 - 268.
2. 2. Schuind F, Ventura M, Pasteels JL. Idiopathic carpal tunnel syndrome: histologic study of flexor tendon synovium. J Hand Surg Am. 1990; 15: 497 - 503.
3. 3. Rosenbaum R. Carpal Tunnel Syndrome. In: Johnson RT, Griffin WJ: Current therapy in neurologic disease. 5th ed USA: Mosby-Year book Inc.,; 1997. pp.374 - 377.
4. 4. Aygül R, Deniz O, Ulvi H. Association of different electrophysiological parameters with age in Carpal Tunnel Syndrome. MJAU 2004; 36: 77 - 82.
5. 5. van Dijk MA, Reitsma JB, Fischer JC, Sanders GT. Indications for requesting laboratory tests for concurrent diseases in patients with carpal tunnel syndrome: a systematic review. Clin Chem 2003; 49: 1437 - 1444.
6. 6. Hirata H, Nagakura T, Tsujii M, et al. The relationship of VEGF and PGE2 expression to extracellular matrix remodelling of the tenosynovium in the carpal tunnel syndrome. J Pathol. 2004; 204: 605 - 612.
7. 7. Joshi P, Lele V. Lighting the tunnel: FDG PET/CT findings leading to incidental diagnosis of carpal tunnel syndrome. Clin Nucl Med 2014; 39: 78 - 79.
8. 8. Oczenski W, Fitzgerald RD, Schwarz S. Prokalsitonin: a new parameter for the diagnosis of bacterial infection in the perioperative period. Eur J Anaesthesiol 1998; 15: 202 - 209.

9. 9. Carrol ED, Thomson AP, Hart CA. Procalcitonin as a marker of sepsis. Int J Antimicrob Agents 2002; 20: 1 - 9.
10. 10. Saez-Lorens X, Lagrutta F. The acute phase reaction during bacterial infection and its clinical impact in children. Pediatr Infect Dis J. 1993; 12: 83 - 87.
11. 11. American Academy of Neurology Practice parameter for carpal tunnel syndrome (summary statement): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1993; 43: 2406 - 2409.
12. 12. Kurt S, Çevik B, Kaplan Y, et al. The relationship between Boston Questionnaire and electrophysiological findings in Carpal Tunnel Syndrome. Archives of Neuropsychiatry 2010; 47: 237 - 240.
13. 13. Cevik MU, Altun Y, Uzar E, et al. Diagnostic value of F-wave inversion in patients with early carpal tunnel syndrome Neurosci Lett. 2012; 508: 110 - 113.
14. 14. Yildirim A, Bulut HT, Ekmekci B, et al. Use of diffusion tensor imaging for nonsurgical treatments of carpal tunnel syndrome. Muscle Nerve. 2014 Dec; 50(6): 950 - 955.
15. 15. Levine DW, Simmons BP, Koris MJ, et al. A self- administered questionnaire for the assessment of severity of symptoms and functional status in carpal tunnel syndrome. J Bone Surg (Am) 1993; 75: 1585 - 1592.
16. 16. Stevens JC. AAEM minimonograph #26: the electrodiagnosis of carpal tunnel syndrome.American Association of Electrodiagnostic Medicine. Muscle Nerve 1997; 20: 1477 - 1486.
17. 17. Bland JD. Carpal tunnel syndrome. Curr Opin Neurol 2005; 18: 581 - 585.
18. 18. Werner RA, Andary M. Carpal tunnel syndrome: pathophysiology and clinical neurophysiology. Clin Neurophysiol 2002; 113: 1373 - 1381.
19. 19. Sandek A, Springer J, Habedank D, et al. Procalcitonin-guided antibiotic treatment in heart failure. Lancet 2004; 363(9420): 1555; author reply 1555 - 1556.
20. 20. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004; 363(9409): 600 - 607.
21. 21. Schröder J, Staubach KH, Zabel P, et al. Procalcitonin as a marker of severity in septic shock. Langenbecks Arch Surg. 1999; 384: 33 - 38.
22. 22. Balci C, Sivaci R, Akbulut G, Karabekir HS. Procalcitonin levels as an early marker in patients with multiple trauma under intensive care. J Int Med Res. 2009; 37: 1709 - 1717.
23. 23. Li YM, Liu XY. Serum levels of procalcitonin and high sensitivity C-reactive protein areassociated with long-term mortality in acute ischemic stroke. J Neurol Sci. 2015; 352: 68 - 73.
24. 24. Maruna P, Nedelniklova K, Gürlich R. Physiology and genetics of procalcitonin Physiol Res. 2000; 49 Supply 1: S57 - 61.
25. 25. Vanderschueren S, Deeren D, Knockaert DC, et al. Extremely elevated C-reactive protein. Eur J Intern Med 2006; 17: 430 - 433.
26. 26. Nijsten MW, Olinga P. The TH, et al. Procalcitonin behaves as a fast responding acute phase protein invivo and in vitro. Crit Care Med 2000; 28: 458 - 461.
27. 27. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79: 1605 - 1608.
28. 28. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Medicine 2011; 9:107.
29. 29. Ozgenel GY, Bayraktar A, Ozbek S, et al. Carpal Tunnel Syndrome: Retrospective Analysis of 92 Cases. Uludağ Medical Journal 2010; 36: 95 - 98.
30. 30. Oh YM, Ma TZ, Kwak YG, Eun JP. Proteomic evaluation to identify biomarkers for carpal tunnel syndrome: a comparative serum analysis. Connect Tissue Res 2013; 54: 76 - 81.
31. 31. Takasu S, Takatsu S, Kunitomo Y. Serum hyaluronic acid and interleukin-6 as possible markers of carpal tunnel syndrome in chronic hemodialysis patients. Artificial organs 1994; 18: 420 - 424.
32. 32. Curatola G, Malara E, Sisca S, et al. Biological markers of inflammation and carpal tunnel syndrome in dialysis patients. Nephron. 1990; 56: 453 - 454.
33. 33. Freeland AE, Tucci MA, Barbieri RA, et al. Biochemical evaluation of serum and flexor tenosynovium in carpal tunnel syndrome. Microsurgery 2002; 22: 378- 385.
34. 34. Tutoglu A, Boyacı A, Kocatürk Ö, et al. The relationship of carpal tunnel syndrome and mean platelet volume in geriatric patients. Gaziantep Med J. 2014; 20: 182 - 185.